Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti–SARS-CoV-2 antibodies in the absence of CXCL13
-
- Marne Azarias Da Silva
- INSERM-U1124, Université Paris Cité, Paris, France.
-
- Pierre Nioche
- INSERM-U1124, Université Paris Cité, Paris, France.
-
- Calaiselvy Soudaramourty
- INSERM-U1124, Université Paris Cité, Paris, France.
-
- Anne Bull-Maurer
- Université de Tours, INSERM, UMR1259 MAVIVH, Tours, France.
-
- Mounira Tiouajni
- INSERM-U1124, Université Paris Cité, Paris, France.
-
- Dechuan Kong
- Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
-
- Ouafa Zghidi-Abouzid
- CHU de Québec-Université Laval Research Center, Québec City, Québec, Canada.
-
- Morgane Picard
- INSERM-U1124, Université Paris Cité, Paris, France.
-
- Ana Mendes-Frias
- Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
-
- André Santa-Cruz
- Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
-
- Alexandre Carvalho
- Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
-
- Carlos Capela
- Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
-
- Jorge Pedrosa
- Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
-
- António Gil Castro
- Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
-
- Paul Loubet
- Service des Maladies Infectieuses et Tropicales, CHU de Nîmes, Nîmes, France.
-
- Albert Sotto
- Service des Maladies Infectieuses et Tropicales, CHU de Nîmes, Nîmes, France.
-
- Laurent Muller
- Service de Réanimation Chirugicale, CHU de Nîmes, Nîmes, France.
-
- Jean-Yves Lefrant
- Service de Réanimation Chirugicale, CHU de Nîmes, Nîmes, France.
-
- Claire Roger
- Service de Réanimation Chirugicale, CHU de Nîmes, Nîmes, France.
-
- Pierre-Géraud Claret
- Urgences Médico-Chirugicales Hospitalisation, CHU de Nîmes, Nîmes, France.
-
- Sandra Duvnjak
- Service de Gérontologie et Prévention du Vieillissement, CHU de Nîmes, Nîmes, France.
-
- Tu-Anh Tran
- Service de Pédiatrie, CHU de Nîmes, Nîmes, France.
-
- Kenzo Tokunaga
- Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
-
- Ricardo Silvestre
- Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
-
- Pierre Corbeau
- Institut de Génétique Humaine, UMR9002 CNRS-Université de Montpellier, Montpellier, France.
-
- Fabrizio Mammano
- INSERM-U1124, Université Paris Cité, Paris, France.
-
- Jérôme Estaquier
- INSERM-U1124, Université Paris Cité, Paris, France.
説明
<jats:p>Since the initial spread of severe acute respiratory syndrome coronavirus 2 infection, several viral variants have emerged and represent a major challenge for immune control, particularly in the context of vaccination. We evaluated the quantity, quality, and persistence of immunoglobulin G (IgG) and IgA in individuals who received two or three doses of messenger RNA (mRNA) vaccines, compared with previously infected vaccinated individuals. We show that three doses of mRNA vaccine were required to match the humoral responses of preinfected vaccinees. Given the importance of antibody-dependent cell-mediated immunity against viral infections, we also measured the capacity of IgG to recognize spike variants expressed on the cell surface and found that cross-reactivity was also strongly improved by repeated vaccination. Last, we report low levels of CXCL13, a surrogate marker of germinal center activation and formation, in vaccinees both after two and three doses compared with preinfected individuals, providing a potential explanation for the short duration and low quality of Ig induced.</jats:p>
収録刊行物
-
- Science Advances
-
Science Advances 9 (31), 2023-08-04
American Association for the Advancement of Science (AAAS)
